Summary & Overview
HCPCS C9086: Injection, Anifrolumab-fnia, 1 mg
HCPCS Level II code C9086 designates a unit of anifrolumab-fnia, recorded as “Injection, anifrolumab-fnia, 1 mg.” Anifrolumab-fnia is a biologic immunomodulator used in specialty care and administered by injection or infusion in outpatient infusion centers or ambulatory clinics. Accurate coding of this product affects drug billing, inventory management, and payer coverage determinations for high-cost specialty therapies nationwide.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a national perspective on coding and billing considerations for C9086, addressing reimbursement benchmarks, payer coverage themes, and operational implications for infusion centers and specialty clinics.
Readers will find: a concise explanation of the code and clinical context; an overview of typical sites of service and service line implications; coverage and reimbursement themes across major national payers; and practical benchmarks and policy points that affect claims processing and drug cost management. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9086 represents Injection, anifrolumab-fnia, 1 mg. This code describes the drug product and the administered unit of measure for anifrolumab-fnia, an intravenous or subcutaneous biologic therapy used in specialty immunology treatment contexts.
Service Type: Drug administration (biologic injection)
Typical Site of Service: Outpatient infusion center or clinic; specialty infusion or ambulatory care setting
Clinical & Coding Specifications
Clinical Context
A 48-year-old female with moderate-to-severe systemic lupus erythematosus (SLE) with active cutaneous and joint involvement presents for scheduled intravenous/subcutaneous biologic therapy. The prescribing rheumatologist has ordered C9086 (injection, anifrolumab-fnia, 1 mg) to be administered in the outpatient infusion clinic as part of a repeat dosing regimen. The clinical workflow includes verification of indication and prior authorization, medication reconciliation, assessment of vital signs and infection risk, patient education on infusion-related reactions, preparation and dose calculation by the pharmacy, administration by an RN in the infusion chair, monitoring for immediate adverse events for at least 30–60 minutes post-injection, and documentation of lot, dose, route, and any reactions in the medical record. Typical sites of service are outpatient infusion centers, hospital-owned infusion clinics, and physician office-based infusion suites. The patient scenario may include concurrent baseline laboratory monitoring (CBC, CMP, TB screening) and coordination with the rheumatology team for ongoing disease activity assessment and scheduling of subsequent doses.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when administration requires substantially greater resources than usual, documented and justified (e.g., unusually prolonged monitoring for severe reaction). |